|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present article describes the effect on glucose of small doses of subcutaneous glucagon to revert hypoglycemia and prevent severe events in small children with type 1 diabetes using a continuous glucose monitoring.
|
31673895 |
2020 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we histologically assessed amylase, insulin, glucagon, lipase and/or trypsinogen in 78 organ donor pancreata, from birth through adulthood in controls and those at various stages of type 1 diabetes.
|
31597639 |
2020 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus.
|
31411498 |
2020 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Optimal regulation of blood glucose level in Type I diabetes using insulin and glucagon.
|
30893335 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changes in gastric emptying and GLP-1 secretion and reduced glucose absorption through glucose-lipid competition may contribute to lower glycemia after a high-glycemic index meal with EVOO in T1D patients.
|
30567626 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The VPP can be used to evaluate automated insulin and glucagon delivery algorithms, so-called artificial pancreas (AP) algorithms that are currently being used to help people with T1D better manage their glucose levels.
|
31344037 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The area under the curve for serum glucagon levels after arginine infusion in FT1DM patients was significantly smaller than that in T1DM, T2DM, or SPIDDM patients but was similar to that in PDM patients.
|
30203124 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most insulin<sup>low</sup> cells contained abundant glucagon and other α-cell markers, suggesting that α-cells drive much of the insulin<sup>low</sup> phenotype in T1D.
|
30552110 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As expected, hypoinsulinemia in T1D was associated with hyperglycemia, low levels of glucagon, hyperlipidemia, significant body fat loss, and increased white adipose tissue expression of Fgf21, a marker for lipolysis.
|
31242337 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasma glucagon levels evaluated using the new enzyme-linked immunosorbent assay were dysregulated in type 1 diabetes patients in respect to plasma glucose levels, suggesting dysregulation of secretion.
|
29768718 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, analysis of purified transplant islet exosome cargoes showed decrease in insulin-containing exosomes, but not glucagon-containing exosomes, indicating selective destruction of transplanted β cells secondary to recurrent T1D autoimmunity.
|
30801971 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that medical treatment of thyroid disease, a severe infection, and glucagon prescription for severe hypoglycemia should raise the suspicion of AD development in adults with T1DM.
|
30476180 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
"Preserved" glucagon secretion in fulminant type 1 diabetes.
|
30411869 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypoglycemia-triggered release of structurally unchanged glucagon from the cMN patch is demonstrated in vitro and in a rat model of type 1 diabetes (T1D).
|
31165524 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preserved glucose response to low-dose glucagon after exercise in insulin-pump-treated individuals with type 1 diabetes: a randomised crossover study.
|
30643924 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
To characterize the pharmacokinetic and pharmacodynamic properties of dasiglucagon, a novel, stable and liquid formulated glucagon analogue, during hypoglycaemic and euglycaemic conditions in adult patients with type 1 diabetes mellitus.
|
30350477 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study showed that a majority of our participants with type 1 diabetes were interested in using low-dose glucagon for the treatment of mild hypoglycemia.
|
31552599 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nevertheless, growing evidence supports a concomitant implication of glucagon secreting α cells in type I diabetes progression.
|
31130919 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined treatment with an incretin-based drug, such as a glucagon-like peptide 1 receptor agonist (GLP-1 RA) or a dipeptidyl peptidase-4 (DPP-4) inhibitor, and basal insulin is a new strategy for improving glucose control in type 1 diabetes mellitus (T1DM).
|
30694794 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The glucagon response to an MMTT in people with long-standing type 1 diabetes is not reduced by the presence of residual beta cells.
|
30612138 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no or very limited availability of glucagon kits and trained staff for management of children with T1DM.
|
31588481 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown.
|
31031712 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a doctor-oriented, questionnaire-based survey of pediatricians and physicians to determine the glucagon prescription rate and identify the reason(s) for its underuse in T1DM patients.
|
30367442 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 RA therapy represents an important add-on therapy option for achieving decreased insulin doses, weight loss, and modest improvements in HbA1c levels without significantly increasing hypoglycemia risk in patients with T1DM.
|
31612934 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was undertaken to examine whether 3 to 4 weeks of therapy with pramlintide or liraglutide might help to blunt postprandial hyperglycemia in T1D by suppressing plasma glucagon responses to mixed-meal feedings.
|
29211871 |
2018 |